NIKKEI 225
27,049.47 +178.17 (+0.66%) HANG SENG
22,418.97 +189.47 (+0.85%) CRUDE OIL
111.94 +0.18 (+0.16%) GOLD FUTURES
1,820.60 -0.60 (-0.03%) DOW
30,946.99 -491.27 (-1.56%) BTC-GBP
16,670.28 -517.88 (-3.01%)
Aerie Pharmaceuticals, Inc. (AERI)
After hours:
| Previous close | 8.12 |
| Open | 8.08 |
| Bid | 7.27 x 800 |
| Ask | 8.50 x 2200 |
| Day's range | 7.75 - 8.14 |
| 52-week range | 4.81 - 17.93 |
| Volume | |
| Avg. volume | 626,474 |
| Market cap | 370.809M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.61 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.67 |
- Business Wire
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
DURHAM, N.C., May 25, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY.
- Zacks
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
- Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
DURHAM, N.C., May 24, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational "COMET-2" study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512.
